Literature DB >> 642709

Hypotensive response to debrisoquine and hydroxylation phenotype.

J R Idle, A Mahgoub, R Lancaster, R L Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 642709     DOI： 10.1016/0024-3205(78)90363-6

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


× No keyword cloud information.
  17 in total

1.  Polymorphism of carbon oxidation of drugs and clinical implications.

Authors:  T P Sloan; A Mahgoub; R Lancaster; J R Idle; R L Smith
Journal:  Br Med J       Date:  1978-09-02

2.  Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.

Authors:  M E Veronese; S McLean
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Debrisoquine oxidation phenotype and susceptibility to lung cancer.

Authors:  A R Boobis; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

4.  The development of molecular epidemiology to elucidate cancer risk and prognosis: a historical perspective.

Authors:  Christine B Ambrosone; Curtis C Harris
Journal:  Int J Mol Epidemiol Genet       Date:  2010-02-20

5.  Genetically determined oxidation capacity and the disposition of debrisoquine.

Authors:  T P Sloan; R Lancaster; R R Shah; J R Idle; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

Review 6.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

7.  Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.

Authors:  L Bertilsson; H J Dengler; M Eichelbaum; H U Schulz
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

8.  The metabolism of [14C]-debrisoquine in man.

Authors:  J R Idle; A Mahgoub; M M Angelo; L G Dring; R Lancaster; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

9.  Polymorphic hydroxylation of perhexiline maleate in man.

Authors:  R G Cooper; D A Evans; E J Whibley
Journal:  J Med Genet       Date:  1984-02       Impact factor: 6.318

10.  Evidence of different metabolic phenotypes in humans.

Authors:  Michael Assfalg; Ivano Bertini; Donato Colangiuli; Claudio Luchinat; Hartmut Schäfer; Birk Schütz; Manfred Spraul
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-29       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.